托珠单抗对院外心脏骤停后炎症的调节及其与临床状态、心肌和脑损伤的关联
该研究为IMICA试验的预设亚组分析,纳入80例昏迷的院外心脏骤停(OHCA)患者,入院后随机接受托珠单抗或安慰剂输注。炎症通过细胞因子检测、CRP和白细胞分类计数评估;心肌损伤用TnT和NT-proBNP,脑损伤用神经元特异性烯醇化酶(NSE)和神经丝轻链(NFL),临床状态用SOFA评分和血管活性-正性肌力评分(VIS)。结果显示托珠单抗组IL-5、IL-6、IL-17、中性粒细胞、单核细胞计数及VIS受影响(均p<0.05),而NFL水平无影响;托珠单抗组IL-5和IL-6显著升高,IL-17降低,24和48小时中性粒细胞和单核细胞更低,24小时VIS更低。结论认为托珠单抗调节OHCA后炎症反应,降低血管加压药和正性肌力药物需求。
要点
- 在80例昏迷OHCA患者中,托珠单抗组IL-5、IL-6、IL-17、中性粒细胞、单核细胞计数及VIS受影响(均p<0.05),NFL水平无影响。
- 托珠单抗组IL-5和IL-6显著升高,IL-17降低。
- 托珠单抗组24和48小时中性粒细胞和单核细胞低于安慰剂组,24小时VIS低于安慰剂组。
- 托珠单抗组中性粒细胞和单核细胞与TnT、NSE、NFL、SOFA评分和VIS评分存在多重相关性,安慰剂组无此相关性。
- NT-proBNP、NFL和SOFA评分在两组中均与CRP相关。
适用人群与场景
- 昏迷的院外心脏骤停(OHCA)患者,入院时纳入,共80例。
处置流程与药物剂量
- 入院后随机接受托珠单抗或安慰剂输注(具体剂量、途径和频次原文未写明)。
研究设计与关键结果
- 研究类型:IMICA试验(NCT03863015)的预设亚组分析;样本量80例昏迷OHCA患者,随机接受托珠单抗或安慰剂输注。
- 炎症指标:IL-5、IL-6、IL-17、中性粒细胞及单核细胞计数和VIS受托珠单抗治疗影响(均p<0.05);NFL水平无影响。
- 托珠单抗组IL-5和IL-6显著升高,IL-17降低。
- 托珠单抗组24和48小时中性粒细胞和单核细胞低于安慰剂组,24小时VIS低于安慰剂组。
- 托珠单抗组中性粒细胞和单核细胞与TnT、NSE、NFL、SOFA评分和VIS评分存在多重相关性,安慰剂组无此相关性;NT-proBNP、NFL和SOFA评分在两组中均与CRP相关。
证据类型、等级与局限
- 证据类型:随机对照试验(IMICA试验)的预设亚组分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,OHCA后托珠单抗治疗调节炎症反应,表现为IL-5、IL-6升高,中性粒细胞和单核细胞降低,以及血管加压药和正性肌力药物需求减少。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM: To investigate how the inflammatory response after out-of-hospital cardiac arrest (OHCA) is modulated by blocking IL-6-mediated signalling with tocilizumab, and to relate induced changes to clinical status, myocardial- and brain injury.
METHODS: This is a preplanned substudy of the IMICA trial (ClinicalTrials.gov, NCT03863015). Upon admission 80 comatose OHCA patients were randomized to infusion of tocilizumab or placebo. Inflammation was characterized by a cytokine assay, CRP, and leukocyte differential count; myocardial injury by TnT and NT-proBNP; brain injury by neuron-specific enolase (NSE) and Neurofilament Light chain (NFL), while sequential organ assessment (SOFA) score and Vasoactive-Inotropic Score (VIS) represented overall clinical status.
RESULTS: Responses for IL-5, IL-6, IL-17, neutrophil as well as monocyte counts, and VIS were affected by tocilizumab treatment (all p < 0.05), while there was no effect on levels of NFL. IL-5 and IL-6 were substantially increased by tocilizumab, while IL-17 was lowered. Neutrophils and monocytes were lower at 24 and 48 hours, and VIS was lower at 24 hours, for the tocilizumab group compared to placebo. Multiple correlations were identified for markers of organ injury and clinical status versus inflammatory markers; this included correlations of neutrophils and monocytes with TnT, NSE, NFL, SOFA- and VIS score for the tocilizumab but not the placebo group. NT-proBNP, NFL and SOFA score correlated with CRP in both groups.
CONCLUSIONS: Treatment with tocilizumab after OHCA modulated the inflammatory response with notable increases for IL-5, IL-6, and decreases for neutrophils and monocytes, as well as reduced vasopressor and inotropy requirements.
参考来源
- Meyer MAS, Bjerre M, Wiberg S, et al. Modulation of inflammation by treatment with tocilizumab after out-of-hospital cardiac arrest and associations with clinical status, myocardial- and brain injury. Resuscitation. 2022. PMID: 36572373. doi:10.1016/j.resuscitation.2022.109676
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。